{"id":"ctla4","name":"CTLA-4","symbol":"CTLA4","route":"/targets/ctla4/","asOf":"2026-09-04","xrefs":[{"hgnc":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2505","ensembl":"https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000163599","uniprot":"https://www.uniprot.org/uniprotkb/P16410/entry","alphafold-db":"https://alphafold.ebi.ac.uk/entry/P16410","chembl":"https://www.ebi.ac.uk/chembl/explore/target/CHEMBL2364164","open-targets":"https://platform.opentargets.org/target/ENSG00000163599","civic":"https://civicdb.org/genes/1493/summary","oncokb":"https://www.oncokb.org/gene/CTLA4","cosmic":"https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=CTLA4","cbioportal":"https://www.cbioportal.org/results/mutations?cancer_study_list=msk_impact_2017&gene_list=CTLA4","depmap":"https://depmap.org/portal/gene/CTLA4?tab=overview","human-protein-atlas":"https://www.proteinatlas.org/ENSG00000163599-CTLA4","ncbi-gene":"https://www.ncbi.nlm.nih.gov/gene/1493","omim":"https://www.omim.org/entry/123890"}],"products":[{"id":"adg126","name":"ADG126","status":"phase-2","modality":"monoclonal antibody","route":"/drugs/adg126/"},{"id":"ba3071","name":"BA3071","status":"phase-2","modality":"monoclonal antibody","route":"/drugs/ba3071/"},{"id":"bcd-217","name":"BCD-217","status":"phase-3","modality":"antibody combination (nurulimab and prolgolimab; INN stem -mab; form not stated in the registry record)","route":"/drugs/bcd-217/"},{"id":"botensilimab","name":"Botensilimab","status":"phase-2","modality":"monoclonal antibody","route":"/drugs/botensilimab/"},{"id":"cadonilimab","name":"Cadonilimab","status":"approved","modality":"Bispecific antibody (PD-1×CTLA-4)","route":"/drugs/cadonilimab/"},{"id":"gotistobart","name":"Gotistobart","status":"phase-3","modality":"monoclonal antibody","route":"/drugs/gotistobart/"},{"id":"ipilimumab","name":"Ipilimumab","status":"approved","modality":"Monoclonal antibody (anti-CTLA-4)","route":"/drugs/ipilimumab/"},{"id":"jk08","name":"JK08","status":"phase-2","modality":"fusion protein or cytokine","route":"/drugs/jk08/"},{"id":"lorigerlimab","name":"Lorigerlimab","status":"phase-2","modality":"bispecific antibody","route":"/drugs/lorigerlimab/"},{"id":"tremelimumab","name":"Tremelimumab","status":"approved","modality":"Monoclonal antibody (anti-CTLA-4)","route":"/drugs/tremelimumab/"}],"trials":[{"id":"emerald-3","name":"EMERALD-3","nct":"NCT05301842","phase":"3","status":"positive"},{"id":"nct03036098","name":"Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer","nct":"NCT03036098","phase":"3","status":"active"},{"id":"checkmate-8hw","name":"CheckMate 8HW","nct":"NCT04008030","phase":"3","status":"positive"},{"id":"checkmate-9dw","name":"CheckMate 9DW","nct":"NCT04039607","phase":"3","status":"positive"},{"id":"compassion-16","name":"COMPASSION-16 / AK104-303","nct":"NCT04982237","phase":"3","status":"positive"},{"id":"nadina","name":"NADINA","nct":"NCT04949113","phase":"3","status":"positive"},{"id":"checkmate-915","name":"CheckMate 915","nct":"NCT03068455","phase":"3","status":"negative"},{"id":"cosmic-313","name":"COSMIC-313","nct":"NCT03937219","phase":"3","status":"mixed"},{"id":"himalaya","name":"HIMALAYA","nct":"NCT03298451","phase":"3","status":"positive"},{"id":"nct03164616","name":"Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).","nct":"NCT03164616","phase":"3","status":"active"},{"id":"nct02542293","name":"Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)","nct":"NCT02542293","phase":"3","status":"active"},{"id":"checkmate-648","name":"CheckMate 648","nct":"NCT03143153","phase":"3","status":"positive"},{"id":"dreamseq","name":"DREAMseq (ECOG-ACRIN EA6134)","nct":"NCT02224781","phase":"3","status":"positive"},{"id":"lung-map-s1400i","name":"Lung-MAP S1400I: nivolumab with or without ipilimumab","nct":"NCT02785952","phase":"3","status":"negative"},{"id":"nct02516241","name":"Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer","nct":"NCT02516241","phase":"3","status":"active"},{"id":"checkmate-743","name":"CheckMate 743","nct":"NCT02899299","phase":"3","status":"positive"},{"id":"checkmate-9la","name":"CheckMate 9LA","nct":"NCT03215706","phase":"3","status":"positive"},{"id":"caspian","name":"CASPIAN","nct":"NCT03043872","phase":"3","status":"positive"},{"id":"checkmate-227","name":"CheckMate 227","nct":"NCT02477826","phase":"3","status":"positive"},{"id":"nct02453282","name":"Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)","nct":"NCT02453282","phase":"3","status":"active"},{"id":"checkmate-214","name":"CheckMate 214","nct":"NCT02231749","phase":"3","status":"positive"},{"id":"checkmate-238","name":"CheckMate 238","nct":"NCT02388906","phase":"3","status":"positive"},{"id":"checkmate-067","name":"CheckMate 067","nct":"NCT01844505","phase":"3","status":"positive"},{"id":"keynote-006","name":"KEYNOTE-006","nct":"NCT01866319","phase":"3","status":"positive"},{"id":"ca184-043-ipilimumab","name":"CA184-043","nct":"NCT00861614","phase":"3","status":"negative"},{"id":"nct05732805","name":"A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma","nct":"NCT05732805","phase":"3","status":"active"},{"id":"nct07023315","name":"A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenocarcinoma","nct":"NCT07023315","phase":"3","status":"recruiting"},{"id":"nct05489289","name":"A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection","nct":"NCT05489289","phase":"3","status":"recruiting"},{"id":"nct06617416","name":"A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC","nct":"NCT06617416","phase":"3","status":"recruiting"},{"id":"nct05235516","name":"A Study of AK104/Placebo Combined With Chemoradiotherapy For The Treatment of Locally Advanced Cervical Cancer","nct":"NCT05235516","phase":"3","status":"active"},{"id":"nct05990127","name":"A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer","nct":"NCT05990127","phase":"3","status":"planned"},{"id":"nct06371157","name":"A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepat","nct":"NCT06371157","phase":"3","status":"recruiting"},{"id":"nct05751928","name":"A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma","nct":"NCT05751928","phase":"3","status":"active"},{"id":"nct03873402","name":"A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer","nct":"NCT03873402","phase":"3","status":"active"},{"id":"nct05144854","name":"A Study to Evaluate the Efficacy and Safety of ONO-4538 in Combination With Ipilimumab and Chemotherapy in Chemotherapy-naïve Participants With HER2-negative Unresectable Advanced or Recurrent Gastric Cancer (Including Esophagogastric Junction Cancer)","nct":"NCT05144854","phase":"3","status":"active"},{"id":"nct06566755","name":"Cadonilimab (AK104) Combined With Chemotherapy and Bevacizumab as First-line Treatment for RAS Mutated or Right Sided-metastatic MSS Colorectal Cancer","nct":"NCT06566755","phase":"3","status":"recruiting"},{"id":"nct05883644","name":"Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC)","nct":"NCT05883644","phase":"3","status":"active"},{"id":"nct05557838","name":"Durvalumab Plus Tremelimumab as First-line Treatment in Chinese Patients With uHCC","nct":"NCT05557838","phase":"3","status":"active"},{"id":"nct07815834","name":"FAPI-Guided Radiotherapy With Cadonilimab and Standard Chemotherapy for Colorectal Peritoneal Metastasis: A Phase III Randomized Controlled Trial (TORHC-PM02)","nct":"NCT07815834","phase":"3","status":"planned"},{"id":"nct06097728","name":"MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma","nct":"NCT06097728","phase":"3","status":"active"},{"id":"nct07412613","name":"Neoadjuvant/Adjuvant AK104 in Microsatellite Instability-high or Mismatch Repair-deficient, Resectable Colon Cancer","nct":"NCT07412613","phase":"3","status":"recruiting"},{"id":"nct03391869","name":"Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer","nct":"NCT03391869","phase":"3","status":"active"},{"id":"nct05671510","name":"ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors","nct":"NCT05671510","phase":"3","status":"active"},{"id":"nct04585490","name":"Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC","nct":"NCT04585490","phase":"3","status":"recruiting"},{"id":"nct06921785","name":"Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma","nct":"NCT06921785","phase":"3","status":"recruiting"},{"id":"nct03682068","name":"Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer","nct":"NCT03682068","phase":"3","status":"active"},{"id":"nct06490536","name":"The Sagittarius Trial","nct":"NCT06490536","phase":"3","status":"recruiting"},{"id":"nct04960709","name":"Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse Cisplatin","nct":"NCT04960709","phase":"3","status":"active"},{"id":"nct06581406","name":"A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult P","nct":"NCT06581406","phase":"2/3","status":"recruiting"},{"id":"nct06221748","name":"DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinoma After Progression on First-line Therapy","nct":"NCT06221748","phase":"2/3","status":"recruiting"},{"id":"nct05987332","name":"IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma","nct":"NCT05987332","phase":"2/3","status":"active"},{"id":"nct04929041","name":"Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Pati","nct":"NCT04929041","phase":"2/3","status":"active"},{"id":"lung-map","name":"Lung-MAP (SWOG S1400 and S1900)","nct":"NCT02154490","phase":"platform","status":"completed"},{"id":"nct05608044","name":"A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer","nct":"NCT05608044","phase":"2","status":"active"},{"id":"niche-2","name":"NICHE-2","nct":"NCT03026140","phase":"2","status":"positive"},{"id":"nct02519348","name":"A Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma","nct":"NCT02519348","phase":"2","status":"active"},{"id":"dart-s1609","name":"DART (SWOG S1609): nivolumab plus ipilimumab in rare tumours","nct":"NCT02834013","phase":"2","status":"active"},{"id":"tapur","name":"TAPUR (Targeted Agent and Profiling Utilization Registry)","nct":"NCT02693535","phase":"2","status":"recruiting"},{"id":"checkmate-142","name":"CheckMate 142","nct":"NCT02060188","phase":"2","status":"positive"},{"id":"checkmate-204","name":"CheckMate 204","nct":"NCT02320058","phase":"2","status":"positive"},{"id":"nci9673","name":"NCI9673","nct":"NCT02314169","phase":"2","status":"mixed"},{"id":"nct07578337","name":"A Clinical Study Evaluating a New Treatment Strategy for Patients With Advanced Pancreatic Cancer Who Have Not Received Prior Treatment for Advanced Disease.","nct":"NCT07578337","phase":"2","status":"planned"},{"id":"nct07052253","name":"A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC.","nct":"NCT07052253","phase":"2","status":"recruiting"},{"id":"nct05859750","name":"A Study of AK104 With Chemotherapy as First-line Treatment in Patients With Advanced Pancreatic Cancer","nct":"NCT05859750","phase":"2","status":"recruiting"},{"id":"nct07227636","name":"A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy","nct":"NCT07227636","phase":"2","status":"recruiting"},{"id":"nct06843434","name":"A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma","nct":"NCT06843434","phase":"2","status":"recruiting"},{"id":"nct07245446","name":"A Study of Ivonescimab in First-Line ES-SCLC","nct":"NCT07245446","phase":"2","status":"recruiting"},{"id":"nct06730347","name":"A Study of Lorigerlimab in Participants With Advanced Solid Tumors","nct":"NCT06730347","phase":"2","status":"recruiting"},{"id":"nct06946797","name":"A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Pre","nct":"NCT06946797","phase":"2","status":"active"},{"id":"nct06008093","name":"A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS","nct":"NCT06008093","phase":"2","status":"active"},{"id":"nct05932212","name":"AK104 for Recurrent or Metastatic Vulvar Cancer","nct":"NCT05932212","phase":"2","status":"recruiting"},{"id":"nct07544784","name":"AK104 Plus Radiotherapy Combined With Standard Therapy Versus Standard Therapy as First-Line Treatment for pMMR/MSS CRLM (APSOC)","nct":"NCT07544784","phase":"2","status":"recruiting"},{"id":"nct06560112","name":"An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer","nct":"NCT06560112","phase":"2","status":"recruiting"},{"id":"nct07635290","name":"Anlotinib+Cadonilimab+PULSAR in Advanced Biliary Tract Cancer","nct":"NCT07635290","phase":"2","status":"active"},{"id":"nct07550088","name":"BAL/BOT/agenT-797 in pMMR CRC With Liver Metastases","nct":"NCT07550088","phase":"2","status":"recruiting"},{"id":"nct04933903","name":"BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab","nct":"NCT04933903","phase":"2","status":"recruiting"},{"id":"nct06367088","name":"Cadonilimab Combined With Chemotherapy as First or Second Line Treatment in Recurrent or Metastatic Triple Negative Breast Cancer","nct":"NCT06367088","phase":"2","status":"recruiting"},{"id":"nct06168786","name":"Cadonilimab Combined With Fruquintinib and SBRT as Athird-line and Posterior Line Treatment in Patients With MSS CRC","nct":"NCT06168786","phase":"2","status":"recruiting"},{"id":"nct06438822","name":"Cadonilimab Combined With Liposomal Irinotecan Plus Leucovorin and Fluorouracil for Advanced Cholangiocarcinoma","nct":"NCT06438822","phase":"2","status":"recruiting"},{"id":"nct06532617","name":"Cadonilimab Combined With S-1 or Capecitabine as Second-line Treatment for Advanced Pancreatic Cancer","nct":"NCT06532617","phase":"2","status":"recruiting"},{"id":"nct04969887","name":"Combination Immunotherapy in Rare Cancers Under InvesTigation","nct":"NCT04969887","phase":"2","status":"active"},{"id":"nct03937830","name":"Combined Treatment of Durvalumab, Bevacizumab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma or Biliary Tract Carcinoma","nct":"NCT03937830","phase":"2","status":"active"},{"id":"nct03482102","name":"Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer","nct":"NCT03482102","phase":"2","status":"active"},{"id":"nct04499053","name":"Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer","nct":"NCT04499053","phase":"2","status":"recruiting"},{"id":"nct05451043","name":"Durvalumab and Tremelimumab in Combination With Propranolol and Chemotherapy for Treatment of Advanced Hepatopancreabiliary Tumors (BLOCKED)","nct":"NCT05451043","phase":"2","status":"recruiting"},{"id":"nct07081633","name":"Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma","nct":"NCT07081633","phase":"2","status":"active"},{"id":"nct06780787","name":"FOLFOX, Botensilimab, and Balstilimab for the Treatment of Localized Rectal Cancer Before Surgery","nct":"NCT06780787","phase":"2","status":"recruiting"},{"id":"nct04238637","name":"Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)","nct":"NCT04238637","phase":"2","status":"active"},{"id":"nct05732389","name":"Immunotherapy in Patients With Early dMMR Rectal Cancer","nct":"NCT05732389","phase":"2","status":"recruiting"},{"id":"nct06789848","name":"Ligufalimab and Cadonilimab in Advanced Liver Cancers","nct":"NCT06789848","phase":"2","status":"recruiting"},{"id":"nct06747845","name":"Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy","nct":"NCT06747845","phase":"2","status":"recruiting"},{"id":"nct06405490","name":"NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC","nct":"NCT06405490","phase":"2","status":"recruiting"},{"id":"nct06941857","name":"NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer","nct":"NCT06941857","phase":"2","status":"recruiting"},{"id":"nct06846268","name":"Neoadjuvant ADG126 and Pembrolizumab in Locally Advanced Colorectal Cancer","nct":"NCT06846268","phase":"2","status":"recruiting"},{"id":"nct07595874","name":"Neoadjuvant Botensilimab and Balstilimab for the Treatment of Advanced Resectable Colorectal Cancer NEST3","nct":"NCT07595874","phase":"2","status":"recruiting"},{"id":"nct07403877","name":"Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer","nct":"NCT07403877","phase":"2","status":"planned"},{"id":"nct05310643","name":"Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC","nct":"NCT05310643","phase":"2","status":"recruiting"},{"id":"nct06342037","name":"NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial","nct":"NCT06342037","phase":"2","status":"recruiting"},{"id":"nct05446298","name":"ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer","nct":"NCT05446298","phase":"2","status":"active"},{"id":"nct03899155","name":"Pan Tumor Rollover Study","nct":"NCT03899155","phase":"2","status":"recruiting"},{"id":"nct06589440","name":"Phase 2 Study of SR-8541A in Combination With Botensilimab and Balstilimab in Subjects With Refractory Metastatic Microsatellite Stable Colorectal Can","nct":"NCT06589440","phase":"2","status":"recruiting"},{"id":"nct05864534","name":"Phase 2a Immune Modulation With Ultrasound for Newly Diagnosed Glioblastoma","nct":"NCT05864534","phase":"2","status":"recruiting"},{"id":"nct07003022","name":"Phase II Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC","nct":"NCT07003022","phase":"2","status":"recruiting"},{"id":"nct06300463","name":"Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases","nct":"NCT06300463","phase":"2","status":"recruiting"},{"id":"nct05845450","name":"Pre-operative Targeted Treatments in Molecularly Selected Resectable Colorectal Cancer (UNICORN)","nct":"NCT05845450","phase":"2","status":"recruiting"},{"id":"nct01843374","name":"Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Subjects With Unresectable Malignant Mesothelioma","nct":"NCT01843374","phase":"2","status":"active"},{"id":"nct07735624","name":"RECTIFY-1: Neoadjuvant Botensilimab + Balstilimab in MSS/pMMR Early Rectal Cancer","nct":"NCT07735624","phase":"2","status":"recruiting"},{"id":"nct07071961","name":"Regorafenib (Reg) and Lorigerlimab (Lor), RELO Regimen, in Treatment of High-risk Patients With Colorectal Cancer With Radiographic Occult Molecular Residual Di","nct":"NCT07071961","phase":"2","status":"recruiting"},{"id":"nct06401005","name":"SBRT, Chemotherapy, and AK104 Neoadjuvant Therapy for Triple-negative Breast Cancer (TNBC)","nct":"NCT06401005","phase":"2","status":"recruiting"},{"id":"nct06680739","name":"Single cEll pRofiling PErsistaNce To ImmuNothErapy","nct":"NCT06680739","phase":"2","status":"recruiting"},{"id":"nct07654530","name":"Sintilimab Combined With Ipilimumab (N01) Plus AG as First-line Therapy for uBTC.","nct":"NCT07654530","phase":"2","status":"active"},{"id":"nct06202313","name":"Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer","nct":"NCT06202313","phase":"2","status":"planned"},{"id":"nct03865082","name":"Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)","nct":"NCT03865082","phase":"2","status":"active"},{"id":"nct03606967","name":"Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer","nct":"NCT03606967","phase":"2","status":"recruiting"},{"id":"nct07551596","name":"Testing the Combination of Anti-Cancer Drugs, Botensilimab (AGEN1181) and Balstilimab (AGEN2034), After Standard Treatment for Colorectal Cancer, Combat Trial","nct":"NCT07551596","phase":"2","status":"recruiting"},{"id":"nct06843551","name":"The Miami \"EMPIRE\" Trial - Eradication of Metastatic Pancreatic Cancer With Immuno-Radiation","nct":"NCT06843551","phase":"2","status":"recruiting"},{"id":"nct03837899","name":"Durvalumab and Tremelimumab for Pediatric Malignancies","nct":"NCT03837899","phase":"1/2","status":"active"},{"id":"checkmate-358","name":"CheckMate 358","nct":"NCT02488759","phase":"1/2","status":"completed"},{"id":"nct07563738","name":"A 2-part Phase 1/2 Open-label Trial on ODM-212","nct":"NCT07563738","phase":"1/2","status":"recruiting"},{"id":"nct05584670","name":"A First-in-human, Dose Escalation and Dose Expansion Study of SAR445877 in Adult Participants With Advanced Solid Tumors","nct":"NCT05584670","phase":"1/2","status":"recruiting"},{"id":"nct05180799","name":"A Phase 1/2 Study of BA3071 in Patients With Solid Tumors","nct":"NCT05180799","phase":"1/2","status":"active"},{"id":"nct04524871","name":"A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Li","nct":"NCT04524871","phase":"1/2","status":"active"},{"id":"nct06530251","name":"A Study of AK112 in Patients With Advanced Hepatocellular Carcinoma (HCC)","nct":"NCT06530251","phase":"1/2","status":"recruiting"},{"id":"nct06362369","name":"A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy","nct":"NCT06362369","phase":"1/2","status":"recruiting"},{"id":"nct05944224","name":"A Study to Efficacy and Safety of SPH4336 Monotherapy or in Combination With Cadonilimab in Patients With Advanced Solid Tumors.","nct":"NCT05944224","phase":"1/2","status":"recruiting"},{"id":"nct07291076","name":"A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unres","nct":"NCT07291076","phase":"1/2","status":"recruiting"},{"id":"nct07293351","name":"A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal ","nct":"NCT07293351","phase":"1/2","status":"recruiting"},{"id":"nct05405595","name":"ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors","nct":"NCT05405595","phase":"1/2","status":"recruiting"},{"id":"nct05904379","name":"AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer","nct":"NCT05904379","phase":"1/2","status":"active"},{"id":"nct06646055","name":"AK112 and Cadonilimab Combined With Chemotherapy for 1L Treatment of Metastatic Pancreatic Cancer","nct":"NCT06646055","phase":"1/2","status":"active"},{"id":"nct03539822","name":"Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies","nct":"NCT03539822","phase":"1/2","status":"recruiting"},{"id":"nct06784648","name":"Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma","nct":"NCT06784648","phase":"1/2","status":"active"},{"id":"nct07355205","name":"First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer","nct":"NCT07355205","phase":"1/2","status":"recruiting"},{"id":"nct05682443","name":"ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC","nct":"NCT05682443","phase":"1/2","status":"active"},{"id":"nct03647163","name":"Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors","nct":"NCT03647163","phase":"1/2","status":"active"},{"id":"nct03907852","name":"Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer","nct":"NCT03907852","phase":"1/2","status":"active"},{"id":"nct06047379","name":"Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis","nct":"NCT06047379","phase":"1/2","status":"recruiting"},{"id":"nct04140526","name":"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC","nct":"NCT04140526","phase":"1/2","status":"active"},{"id":"nct05501665","name":"Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer","nct":"NCT05501665","phase":"1/2","status":"recruiting"},{"id":"nct05620134","name":"Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer","nct":"NCT05620134","phase":"1/2","status":"active"},{"id":"nct05933265","name":"Study of LP-184 in Patients With Advanced Solid Tumors","nct":"NCT05933265","phase":"1/2","status":"active"},{"id":"nct05533697","name":"Study of mRNA-4359 Administered Alone and in Combination With Immune Checkpoint Blockade in Participants With Advanced Solid Tumors","nct":"NCT05533697","phase":"1/2","status":"recruiting"},{"id":"nct07227012","name":"Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a","nct":"NCT07227012","phase":"1/2","status":"recruiting"},{"id":"nct07227415","name":"Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With ","nct":"NCT07227415","phase":"1/2","status":"recruiting"},{"id":"nct05187338","name":"Triplex Checkpoint Inhibitors Therapy for Advanced Solid Tumors","nct":"NCT05187338","phase":"1/2","status":"recruiting"}],"pathways":["pd1-checkpoint","cancer-immunity-cycle","tumor-microenvironment"],"companies":["agenus","akeso","astrazeneca","bioatla","biocad","bms","macrogenics","oncoc4","roche-genentech","sanofi","xilio-therapeutics"],"keyPapers":["paper-checkmate-067-10-year-nejm-2025","paper-bullock-botensilimab-balstilimab-mss-colorectal-nat-med-2024","paper-nadina-nejm-2024","paper-niche-2-nejm-2024","paper-andre-checkmate-8hw-nivolumab-ipilimumab-nejm-2024","paper-rohaas-til-vs-ipilimumab-nejm-2022","paper-asco-irae-guideline-jco-2021","paper-yamamoto-nature","paper-oreilly-durvalumab-tremelimumab-pancreatic-jama-oncol-2019","paper-checkmate-227-n-engl-j-med-2018","paper-ribas-wolchok-checkpoint-blockade-science-2018","paper-keynote-006-pembrolizumab-ipilimumab-melanoma-nejm-2015","paper-feig-cxcl12-fap-cafs-t-cell-exclusion-pnas-2013","paper-pardoll-immune-checkpoint-blockade-nrc-2012","paper-hodi-ipilimumab-melanoma-nejm-2010","paper-royal-ipilimumab-pancreatic-j-immunother-2010","paper-leach-allison-ctla4-blockade-science-1996"],"hotspots":[],"openQuestions":[],"assays":[{"id":"msi-pcr","name":"MSI by PCR (Promega MSI Analysis System and equivalents)","cutoff":"Instability at two or more of five markers (MSI-high); NGS panels report MSI from hundreds of loci"}],"resistance":[],"licence":"CC BY-NC 4.0, attribution to OnCo (https://onco.cc); commercial use needs a licence"}